190 related articles for article (PubMed ID: 7516401)
1. Prostate specific antigen density: a method for differentiating prostate carcinoma from benign prostatic hypertrophy demonstrates ethnic variation.
Martin AA; Clejan S
J La State Med Soc; 1994 Apr; 146(4):163-71. PubMed ID: 7516401
[No Abstract] [Full Text] [Related]
2. [Comment on Grond, A., M. Ostermann-Myrau: Benign and malignant diseases of the prostate].
Grond A
Versicherungsmedizin; 1995 Apr; 47(2):66-7. PubMed ID: 7539193
[No Abstract] [Full Text] [Related]
3. [BIOMARKERS OF EARLY AND DIFFERENTIAL DIAGNOSIS OF PROSTATIC CANCER].
Grygorenko VM; Danylets RO; Vikarchuk MV; Gorbahn LV; Klepko AV
Klin Khir; 2017; (1):54-7. PubMed ID: 30272918
[TBL] [Abstract][Full Text] [Related]
4. [Improved discrimination between prostatic carcinoma and benign prostatic hyperplasia by determination of free prostate-specific antigen percentage].
Wolff JM; Borchers H; Boeckmann W; Habib FK; Jakse G
Urologe A; 1997 May; 36(3):255-8. PubMed ID: 9265347
[TBL] [Abstract][Full Text] [Related]
5. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
Urologiia; 2001; (2):37-40. PubMed ID: 11490716
[TBL] [Abstract][Full Text] [Related]
6. Impact of prostate-specific antigen density in benign prostatic hyperplasia and prostate carcinoma. Preliminary results.
Akdaş A; Dillioğlugil O; Cevik I; Ilker Y
Eur Urol; 1994; 25(4):299-303; discussion 304. PubMed ID: 7519992
[TBL] [Abstract][Full Text] [Related]
7. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
[TBL] [Abstract][Full Text] [Related]
8. [Early detection of prostatic carcinoma: Is PSA screening suitable?].
Kaulen H
Dtsch Med Wochenschr; 2003 May; 128(18):977. PubMed ID: 12755136
[No Abstract] [Full Text] [Related]
9. Relationship between prostate specific antigen density, microvessel density and prostatic volume in benign prostatic hyperplasia and advanced prostatic carcinoma.
Cetinkaya M; Günçe S; Ulusoy E; Aksoy F; Yildiz O; Adsan O; Ozden C
Int Urol Nephrol; 1998; 30(5):581-5. PubMed ID: 9934801
[TBL] [Abstract][Full Text] [Related]
10. [Significance of the PSA-concentration for the detection of prostate cancer].
Stachon A
Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
[TBL] [Abstract][Full Text] [Related]
11. [Present-day possibilities of prostate cancer screening in patients with benign prostatic hyperplasia before and after surgical treatment].
Pushkar' DIu; Rasner PI; Skobelev PP
Urologiia; 2001; (6):48-54. PubMed ID: 11785083
[No Abstract] [Full Text] [Related]
12. Changes in prostate-specific antigen and prostatic acid phosphatase concentration following prostatic examination in benign prostatic hypertrophy and prostate cancer patients.
Romics I; Galamb L
Eur Urol; 1992; 21 Suppl 1():83-6. PubMed ID: 1385137
[TBL] [Abstract][Full Text] [Related]
13. Other assessments: prostate size and prostate specific antigen.
Williams G
BJU Int; 2000 Mar; 85 Suppl 1():31-5. PubMed ID: 10756703
[No Abstract] [Full Text] [Related]
14. [Plasma TGF-beta1 concentrations in patients with prostate carcinoma or benign prostatic hyperplasia].
Lange I; Hammerer P; Knabbe C; Graefen M; Schmahl M; Huland H
Urologe A; 1998 Mar; 37(2):199-202. PubMed ID: 9563135
[TBL] [Abstract][Full Text] [Related]
15. Prostatic specific antigen (PSA).
Alberti C
Minerva Urol Nefrol; 1993 Jun; 45(2):83-4. PubMed ID: 7694380
[No Abstract] [Full Text] [Related]
16. [Additional aids in detection of prostate carcinomas? PSA-prostatic volume quotient, PSA-doubling time, age-dependent PSA reference values and PSA in urine].
Pannek J; Brands FH
Urologe A; 2000 Jul; 39(4):324-9. PubMed ID: 10957773
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of benign prostatic hyperplasia and prostate cancer employing prostatic-specific antigen density.
Wolff JM; Scholz A; Boeckmann W; Jakse G
Eur Urol; 1994; 25(4):295-8; discussion 304. PubMed ID: 7519991
[TBL] [Abstract][Full Text] [Related]
18. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
Ornstein DK; Rayford W; Fusaro VA; Conrads TP; Ross SJ; Hitt BA; Wiggins WW; Veenstra TD; Liotta LA; Petricoin EF
J Urol; 2004 Oct; 172(4 Pt 1):1302-5. PubMed ID: 15371828
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range.
Ito K; Miyakubo M; Sekine Y; Koike H; Matsui H; Shibata Y; Suzuki K
World J Urol; 2013 Apr; 31(2):305-11. PubMed ID: 22903772
[TBL] [Abstract][Full Text] [Related]
20. Inter-relation between measurement of serum prostatic specific antigen and transrectal ultrasound in the diagnosis of benign prostatic hyperplasia and prostatic cancer.
Clements R; Etherington RJ; Griffiths GJ; Peeling WB; Hughes H; Penney MD
Br J Urol; 1992 Aug; 70(2):183-7. PubMed ID: 1382795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
